The researchers then tested the capacity of the modified cells to kill human multiple
myeloma cells in laboratory studies and an animal model.
Not exact matches
Multiple
myeloma causes tumors to grow
in the bone marrow, preventing the production of normal blood
cells.
Analyzing a database of nearly 800 multiple
myeloma patient samples, they discovered that 162 patients with low ADAR1 levels
in their tumor
cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.
«Several major advances
in recent years have been good news for multiple
myeloma patients, but those new drugs only target terminally differentiated cancer
cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem
Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hea
Cell Clinical Center, director of the CIRM Alpha Stem
Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hea
Cell Clinic at UC San Diego and director of stem
cell research at Moores Cancer Center at UC San Diego Hea
cell research at Moores Cancer Center at UC San Diego Health.
They also determined that blocking the enzyme reduces multiple
myeloma regeneration
in experimental models derived from patient cancer
cells.
They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem
cells in multiple
myeloma models.
Researchers used tissue and blood samples to show that the gammopathy (a precursor to
myeloma)
in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor
cells in nearly a third of
myeloma patients are directed against such lipids.
An update search enlarged the pool of study data, but did not change the content of the conclusion of the benefit assessment of stem
cell transplantation (SCT) for multiple
myeloma conducted
in 2012.
In our study, as BMI increased, we started seeing an increase in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explaine
In our study, as BMI increased, we started seeing an increase
in the ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explaine
in the ability of multiple
myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explained.
But
in multiple
myeloma, plasma
cells grow out of control
in the bone marrow, crowding out healthy
cells.
In mice, the Runx2 knock - in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease sprea
In mice, the Runx2 knock -
in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease sprea
in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original
myeloma cells; conversely, the Runx2 knock - down
cells had less tumor growth and disease spread.
«Taken together, these results support the hypothesis that multiple
myeloma cells express bone - related genes
in a Runx2 - dependent fashion that mimics bone marrow resident
cells and likely contributes to tumor survival and growth
in the bone microenvironment,» Yang and colleagues wrote
in the paper.
«Therefore, the targeting of Runx2 expression
in multiple
myeloma cells may represent a new therapeutic strategy for the treatment of aggressive multiple
myeloma.»
«This suggests that Runx2 levels
in myeloma cells may be a gene predictor of a patient's prognosis, good or bad,» Yang said.
Researchers have designed a nanoparticle - based therapy that is effective
in treating mice with multiple
myeloma, a cancer of immune
cells in the bone marrow.
«We know multiple
myeloma cells will anchor into bone marrow, and fat
cells in the bone marrow will support the growth and spread of the cancer.
Healthy plasma
cells produce antibodies that fight infection
in the body, but
myeloma cells produce high levels of abnormal antibodies that, when the cancer
cells accumulate, they crowd out production of other important blood
cells, both red and white.
In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cell
In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple
myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher
in the multiple myeloma cell
in the multiple
myeloma cells.
Researchers at Washington University School of Medicine
in St. Louis have developed a nanotherapy that is effective
in treating mice with multiple
myeloma, a cancer of bone marrow immune
cells.
The researchers also tested a Runx2 knock - down variant of a human multiple
myeloma cell line and found that it produced significantly less tumor growth
in immunodeficient mice than the original human multiple
myeloma cells.
Whether investigating fat
cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple
myeloma, approaches beyond attacking cancer
cells are needed
in the fight against many cancers.
The study, «Lenalidomide (LEN) maintenance (MNTC) after high - dose melphalan and autologous stem
cell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, Jun
cell transplant (ASCT)
in multiple
myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma
Cell Dyscrasia oral abstract session Friday, Jun
Cell Dyscrasia oral abstract session Friday, June 3.
Being overweight or obese has been known to increase the risk of multiple
myeloma, a cancer of the plasma
cells in the blood and bone marrow that develops more often after age 60.
In multiple
myeloma, normal plasma
cells transform into malignant
myeloma cells and produce large quantities of toxic abnormal immunoglobulin called monoclonal protein that can damage multiple organs.
Multiple
myeloma is preceded by a blood disorder called monoclonal gammopathy of undetermined significance (MGUS)
in which abnormal plasma
cells produce many copies of an antibody protein.
The group looked at an oncogene, AF1q discovered
in Tse's lab, which is expressed
in hematological cancer
cells and is known to be related to multiple
myeloma.
Multiple
myeloma is a cancer of plasma
cells in the blood that causes tumor growths
in bone marrow.
Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of
myeloma cells with immune
cells from a family donor (immunotherapy), the study resulted
in a total cure rate of 41 %, a record level using this strategy.
Bortezomib, used most commonly
in treating multiple
myeloma, is a proteasome inhibitor that prevents cancer
cells from clearing toxic material.
«The treatment of multiple
myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical
myeloma has improved significantly
in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor
cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple
Myeloma Center, and the R.J. Corman professor at Harvard Medical
Myeloma Center, and the R.J. Corman professor at Harvard Medical School.
Relative to reactions on naked DNA, there are changes (protections and enhancements)
in the reactivity of guanine residues to dimethyl sulfate within the enhancer sequence
in myeloma, B, and early B
cells, whereas virtually no alterations appear
in cells of non-B lineage.
«T -
cell receptor therapy achieves encouraging clinical responses
in multiple
myeloma: NY - ESO T
cell receptor therapy found to be safe, with no cytokine release syndrome cases.»
After being infused back into patients» bodies, these newly built
cells both multiply and seek out a peptide expressed by the antigens NY - ESO - 1 and LAGE - 1 found
in multiple
myeloma cancer
cells.
Results from a clinical trial investigating a new T
cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer
cells demonstrated a clinical response
in 80 percent of multiple
myeloma patients with advanced disease after undergoing autologous stem
cell transplants (ASCT).
Multiple
myeloma is a cancer of the infection - fighting plasma
cells, part of the immune system found mainly
in bone marrow.
In examining these remaining
myeloma cells, the Yale team discovered a previously unidentified biologic pathway induced by the immune modulating drugs that enabled the residual cancer
cells to survive and proliferate.
Antibodies only bind to target
cells Peptide antibodies developed by Kwak and co-discoverer, Hong Qin, Ph.D., assistant professor of Lymphoma /
Myeloma, wipe out MDSCs
in the blood, spleen and tumor
cells of mice without binding to other white blood
cells or dendritic
cells involved
in immune response.
In the 1990s the U.S. Food and Drug Administration approved its use in the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of lepros
In the 1990s the U.S. Food and Drug Administration approved its use
in the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of lepros
in the treatment of both multiple
myeloma (a form of cancer that affects plasma
cells) and the complications of leprosy.
The discovery was made by developing a mouse model of the disease that enabled researchers to track which of 15 genetic groups — or subclones — of
myeloma cells spread beyond their initial site
in the animals» hind legs.
The team designed a different approach to study the therapy
in myeloma, adding
in an infusion of the patient's own stem
cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.
Although it is among the most highly metastatic of all cancers, multiple
myeloma is driven to spread by only a subset of the
myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found
in a study presented at the annual meeting of the American Society of Hematology (ASH).
A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune
cells might effectively treat multiple
myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths
in 2014
Multiple
myeloma is a blood cancer that forms
in a type of white blood
cell called a plasma
cell.
The researchers grew the modified
cells in the lab to increase their numbers and then injected them into an animal model where they again killed human
myeloma cells.
Bradner and Mitsiades had reported
in Cell in 2011 that the inhibitor blocks the Myc cancer gene and thereby slows the growth of multiple
myeloma tumors
in mice.
Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem
Cell Memory Product
in Patients with Relapsed / Refractory Multiple
Myeloma
on Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem
Cell Memory Product
in Patients with Relapsed / Refractory Multiple
Myeloma
We have one of the most comprehensive CAR T
cell programs
in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials
in the coming year, including for patients with multiple
myeloma, prostate cancer, liver cancer and breast cancer.
The laboratory is interested
in mechanisms by which interactions between neutrophils and multiple
myeloma cells promote disease progression and chemoresistance.
Multiple
myeloma preferentially localizes
in the bone marrow where the majority of surrounding
cells are represented by mature and immature neutrophils.